HOOKIPA Pharma Inc.
Ilian Tchakov has extensive experience in the pharmaceutical industry, with a focus on clinical research and development in the field of oncology. Ilian currently holds the position of VP Immuno-Oncology, Clinical Research & Development at HOOKIPA Pharma Inc. Prior to this, they served as the VP of Clinical Development at MiNA Therapeutics from 2021 to 2023. From 2016 to 2021, Ilian was the Executive Director of Clinical Development, Oncology at Eisai Oncology Medical. Ilian started their career in 2006 as a Clinical Research Physician in Oncology at AstraZeneca, where they worked until 2016.
Ilian Tchakov's education history includes studying at a medical school. The specific years, degree obtained, and field of study are not provided.
This person is not in any offices
HOOKIPA Pharma Inc.
At HOOKIPA, we envision a world in which cancers and infectious diseases can be chronically managed or eradicated. HOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical-stage biopharmaceutical company advancing the field of immunotherapy through the development of new immunotherapies based on our proprietary arenavirus platform, which is designed to mobilize and amplify targeted T cells and thereby fight or prevent serious disease. Our pipeline includes wholly owned investigational arenaviral immunotherapies targeting HPV16+ cancers, prostate cancer, KRAS-mutated cancers (including colorectal, pancreatic and lung), and other undisclosed programs. In addition, HOOKIPA aims to develop functional cures for HBV and HIV in collaboration with Gilead. As a company, we fight for innovation; we challenge ourselves to act authentically and transparently; we thrive on our differences; and we go for it, never giving up in our efforts to eliminate the suffering of people with cancer and infectious disease. To learn more please visit www.hookipapharma.com.